KR20230129628A - 항-섬유화 요법을 투여하는 방법 - Google Patents

항-섬유화 요법을 투여하는 방법 Download PDF

Info

Publication number
KR20230129628A
KR20230129628A KR1020237029765A KR20237029765A KR20230129628A KR 20230129628 A KR20230129628 A KR 20230129628A KR 1020237029765 A KR1020237029765 A KR 1020237029765A KR 20237029765 A KR20237029765 A KR 20237029765A KR 20230129628 A KR20230129628 A KR 20230129628A
Authority
KR
South Korea
Prior art keywords
compound
subject
auc
administration
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237029765A
Other languages
English (en)
Korean (ko)
Inventor
린 판
도로시 쓰윙 청
제프리 마크 해리스
인디아나 스트롬붐
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20230129628A publication Critical patent/KR20230129628A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020237029765A 2016-11-30 2017-11-29 항-섬유화 요법을 투여하는 방법 Ceased KR20230129628A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662428163P 2016-11-30 2016-11-30
US62/428,163 2016-11-30
US201662432425P 2016-12-09 2016-12-09
US62/432,425 2016-12-09
PCT/US2017/063549 WO2018102323A1 (en) 2016-11-30 2017-11-29 Methods of administering anti-fibrotic therapy
KR1020227034429A KR102575344B1 (ko) 2016-11-30 2017-11-29 항-섬유화 요법을 투여하는 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227034429A Division KR102575344B1 (ko) 2016-11-30 2017-11-29 항-섬유화 요법을 투여하는 방법

Publications (1)

Publication Number Publication Date
KR20230129628A true KR20230129628A (ko) 2023-09-08

Family

ID=60655162

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237029765A Ceased KR20230129628A (ko) 2016-11-30 2017-11-29 항-섬유화 요법을 투여하는 방법
KR1020197013644A Ceased KR20190089862A (ko) 2016-11-30 2017-11-29 항-섬유화 요법을 투여하는 방법
KR1020227034429A Active KR102575344B1 (ko) 2016-11-30 2017-11-29 항-섬유화 요법을 투여하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197013644A Ceased KR20190089862A (ko) 2016-11-30 2017-11-29 항-섬유화 요법을 투여하는 방법
KR1020227034429A Active KR102575344B1 (ko) 2016-11-30 2017-11-29 항-섬유화 요법을 투여하는 방법

Country Status (11)

Country Link
US (3) US11207304B2 (cg-RX-API-DMAC7.html)
EP (2) EP3548025A1 (cg-RX-API-DMAC7.html)
JP (3) JP2020502054A (cg-RX-API-DMAC7.html)
KR (3) KR20230129628A (cg-RX-API-DMAC7.html)
CN (1) CN110087651A (cg-RX-API-DMAC7.html)
AU (3) AU2017366881A1 (cg-RX-API-DMAC7.html)
CA (2) CA3045455A1 (cg-RX-API-DMAC7.html)
IL (3) IL299447A (cg-RX-API-DMAC7.html)
MX (3) MX2019006143A (cg-RX-API-DMAC7.html)
TW (3) TWI891129B (cg-RX-API-DMAC7.html)
WO (1) WO2018102323A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI891129B (zh) 2016-11-30 2025-07-21 美商基因科技公司 投與抗纖維化療法之方法
CN114129517A (zh) * 2020-09-03 2022-03-04 苏州爱科百发生物医药技术有限公司 一种ak3287制剂及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
TWI891129B (zh) 2016-11-30 2025-07-21 美商基因科技公司 投與抗纖維化療法之方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Adithan C. Food and drug bioavailability. The Indian Journal of Medical Research. 631-633 (2005.05.01.)
Winstanley PA, Orme ML. The effects of food on drug bioavailability. Br J Clin Pharmacol. 621-8 (1989.12.01.)

Also Published As

Publication number Publication date
EP4470624A3 (en) 2025-01-08
AU2025238129A1 (en) 2025-10-23
AU2017366881A1 (en) 2019-05-30
EP4470624A2 (en) 2024-12-04
KR20220139450A (ko) 2022-10-14
WO2018102323A1 (en) 2018-06-07
TW201825093A (zh) 2018-07-16
JP2020502054A (ja) 2020-01-23
AU2023263548B2 (en) 2025-10-16
US20240197693A1 (en) 2024-06-20
TW202539656A (zh) 2025-10-16
IL289544A (en) 2022-03-01
AU2023263548A1 (en) 2023-11-30
TWI891129B (zh) 2025-07-21
IL289544B2 (en) 2023-06-01
TWI826361B (zh) 2023-12-21
JP2022058873A (ja) 2022-04-12
TW202412795A (zh) 2024-04-01
MX2020011766A (es) 2020-11-24
US11925624B2 (en) 2024-03-12
US11207304B2 (en) 2021-12-28
IL266480A (en) 2019-07-31
KR20190089862A (ko) 2019-07-31
CN110087651A (zh) 2019-08-02
JP7495951B2 (ja) 2024-06-05
US12310951B2 (en) 2025-05-27
CA3247781A1 (en) 2025-07-09
IL299447A (en) 2023-02-01
US20190321344A1 (en) 2019-10-24
US20220184046A1 (en) 2022-06-16
KR102575344B1 (ko) 2023-09-06
CA3045455A1 (en) 2018-06-07
MX2023003924A (es) 2023-04-26
JP2023139157A (ja) 2023-10-03
MX2019006143A (es) 2019-10-17
EP3548025A1 (en) 2019-10-09

Similar Documents

Publication Publication Date Title
KR102105857B1 (ko) 날트렉손 요법에서 약물 생체이용률의 증가
US12310951B2 (en) Methods of administering anti-fibrotic therapy
JP7466822B2 (ja) 亜鉛-γ-PGA組成物およびがんを処置するための方法
US20220105087A1 (en) Increasing Drug Bioavailability In Naltrexone Therapy
HK40012787A (en) Methods of administering anti-fibrotic therapy

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230831

Application number text: 1020227034429

Filing date: 20221004

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20230926

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231106

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240603

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231106

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I